Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

View ORCID ProfileNatalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, View ORCID ProfileAnne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
doi: https://doi.org/10.1101/2022.05.06.22274690
Natalia Martin Orozco
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalia Martin Orozco
  • For correspondence: natalia@providencetherapeutics.com
Noah Vale
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Mihic
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talya Amor
bLMC Manna Research-Toronto. 2291 Kipling Avenue, Unit 117B, Toronto, ON, M9W 4L6, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Reiter
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuko Arita
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reuben Samson
cDepartment of Molecular Genetics, University of Toronto. 1 King’s College Cir, Rm 4396, Toronto, ON, M5S 1A8, Canada
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Queenie Hu
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Claude Gingras
cDepartment of Molecular Genetics, University of Toronto. 1 King’s College Cir, Rm 4396, Toronto, ON, M5S 1A8, Canada
dLunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, 600 University Ave, Toronto, ON M5G 1X5, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne-Claude Gingras
Brad Sorenson
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric G. Marcusson
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piyush Patel
aProvidence Therapeutics Holdings. 8832 Blackfoot Trail SE, Ste 120, Calgary, AB, T2J 3J1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: natalia@providencetherapeutics.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

PTX-COVID19-B mRNA vaccine encodes for SARS-CoV-2 Spike protein G614 variant and lacks the proline-proline (986-987 position) mutation present in other COVID-19 vaccines. This Phase 1 observer-blinded, randomized, placebo-controlled, ascending dose study evaluated the safety, tolerability, and immunogenicity of two doses of PTX-COVID19-B vaccine in healthy seronegative adults. Participants received two intramuscular doses, 4 weeks apart, of 16-μg, 40-μg, or 100-μg PTX-COVID19-B. Adverse events were generally mild to moderate, self-resolving, and transient. The most common solicited local and systemic adverse event was pain at the injection site and headache, respectively. After the first immunization, all participants seroconverted, producing high titers of anti-receptor-binding-domain, anti-Spike, and neutralizing antibodies, including neutralizing antibodies against the ancestral viral strain and the Alpha, Beta, and Delta variants of concern, in a dose-dependent way, further increasing over 10-20 times after the second dose. All tested doses of PTX-COVID19-B were safe, well-tolerated, and provided a strong immunogenicity response. The 40-μg dose showed fewer adverse reactions than the 100-μg dose, supporting further investigation of the 40-μg dose.

Clinical Trial Registration ClinicalTrials.gov identifier: NCT04765436 (https://clinicaltrials.gov/ct2/show/NCT04765436)

Competing Interest Statement

N.M.O., L.W., Y.A., B.S., E.G.M., and P.P. are employees of PT. PT received funding for the Phase 1 trial from National Research Council Canada. The development of the B.1.617.2 (Delta) lentiviral assay was supported by the CIHR operating grant to the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to A.-C.G. A.-C.G. is the Canada Research Chair, Tier 1, in Functional Proteomics.

Clinical Trial

NCT04765436

Funding Statement

Providence Therapeutics received funding for the Phase 1 trial from National Research Council Canada.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial got full ethics approval from Advarra 372 Hollandview Trail, Suite 300 Aurora, ON L4G 0A5 Canada IORG Number: 0000635 IRB Registration: 00000971 FWA Number: 00023875

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript.The development of the B.1.617.2 (Delta) lentiviral assay was supported by the CIHR operating grant to the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to A.-C.G. A.-C.G. is the Canada Research Chair, Tier 1, in Functional Proteomics.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 10, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Natalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, Anne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
medRxiv 2022.05.06.22274690; doi: https://doi.org/10.1101/2022.05.06.22274690
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Natalia Martin Orozco, Noah Vale, Alan Mihic, Talya Amor, Lawrence Reiter, Yuko Arita, Reuben Samson, Queenie Hu, Anne-Claude Gingras, Brad Sorenson, Eric G. Marcusson, Piyush Patel
medRxiv 2022.05.06.22274690; doi: https://doi.org/10.1101/2022.05.06.22274690

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1426)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (586)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5019)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)